A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer
Status:
Unknown status
Trial end date:
2021-10-22
Target enrollment:
Participant gender:
Summary
The prognosis of Extensive lymph nodes metastatic(ELM) gastric cancer is poor. Chemotherapy
occasionally converts it to a resectable cancer. Previous studies showed patients with ELM
gastric cancer may obtain a survival benefit from chemotherapy and subsequent curative
surgery. The key of conversion therapy of ELMGC is the high response rate. Apatinib, a novel
targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor activity in the
patients with GC. On the basis of our previous Ahead-G325 study, The purpose of this study is
to investigate the efficacy and safety of S1/Paclitaxel chemotherapy plus Apatinib in the
conversion therapys of ELM gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhejiang Chinese Medical University